# KLOW Peptide Research — Single-Component Study Evidence > KLOW peptide research reviewed by component: KPV anti-inflammatory studies, GHK-Cu transcriptomics and collagen data, BPC-157 tissue-repair models, and TB-500 wound-healing evidence — each cited to source. ## In plain English — how this review is organized KLOW peptide research is best understood component by component: the blend itself has never been tested in a controlled study, so there is no 'KLOW trial' to review. What exists is a body of research on each of the four individual peptides — KPV, GHK-Cu, BPC-157, and TB-500 — conducted separately in cells, animals, and in some cases humans. This page reviews the key study findings for each arm, attribute them to the correct component, and surfaces the most important recent work from 2024-2025. Mechanistic claims stay attached to the constituent that was actually tested. Any claim that KLOW as a blend 'does X' conflates single-component evidence with combination evidence that does not exist. ## KPV — the anti-inflammatory arm KPV (Lys-Pro-Val, 342.44 Da) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone), the 13-residue parent peptide. It is the smallest of the four KLOW components. The defining study: Dalmasso et al. (2008) demonstrated that KPV is transported into intestinal epithelial cells via the PepT1 (SLC15A1) di/tripeptide transporter, a gut transporter that is upregulated under inflammatory conditions, at a Km of approximately 160 micromolar [1]. In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV inhibited NF-kappaB nuclear import and MAPK ERK/p38 signaling and reduced secretion of TNF-alpha, IL-6, IL-1beta, and IL-8. In C57BL/6 mice with DSS- and TNBS-induced colitis, oral KPV in drinking water reduced colitis severity. The PepT1 transporter mechanism is significant for the blend's gut-targeting rationale: inflamed epithelium upregulates PepT1, which means KPV could preferentially reach the tissues where it is most needed. No controlled KPV monotherapy trial has reached regulatory approval. Human data for KPV are limited to delivery-mechanism pilots and the historical lineage of the IBD research program. ## GHK-Cu — the matrix and copper arm GHK-Cu (Gly-His-Lys copper(II), 402.92 Da) is the mass-dominant component of the canonical KLOW vial at roughly 50 of 80 mg — approximately 62.5% by weight. It was first isolated from human plasma by Loren Pickart in 1973. Skin regeneration review (Pickart et al., 2015): GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin [3]. Plasma GHK levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a documented age-related decline. In placebo-controlled clinical work, topical GHK-Cu increased collagen production in 70% of treated women, compared to 50% for vitamin C and 40% for retinoic acid [3]. Documented improvements in skin laxity, clarity, fine lines, wrinkle depth, and density were reported. Transcriptomics (Pickart and Margolina, 2018): GHK modulates expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, increasing expression of 59% of affected genes and suppressing 41% [2]. The strongest signals are on the ubiquitin-proteasome system (41 genes up, 1 down), DNA-repair gene sets, and antioxidant defense. This broad transcriptomic modulation — at low-nanomolar concentrations in cultured fibroblasts — is the basis for GHK-Cu's reputation as a pleiotropic repair regulator. A note on the commonly cited '~4,000 genes' figure: it is an extrapolation; the published ≥50% threshold table reports on the order of 2,100 genes [2]. GHK-Cu also supplies copper for lysyl oxidase, the copper-dependent enzyme that crosslinks collagen and elastin — a direct structural contribution to the matrix-synthesis rationale. ## BPC-157 — the angiogenic and tissue-repair arm BPC-157 (Body Protection Compound 157, 1419.53 Da, CAS 137525-51-0) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a protein isolated from human gastric juice, originally developed as PL 14736 for inflammatory bowel disease. Achilles tendon study (Staresinic et al., 2003): BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, at doses of 10 microg, 10 ng, or 10 pg per rat by intraperitoneal injection once daily. In vitro, it stimulated tendocyte (tendon fibroblast) outgrowth [4]. This remains one of the most frequently cited BPC-157 tissue-repair studies. NSAID-toxicity model (Ilic et al., 2011): BPC-157 counteracted diclofenac-induced GI, liver, and encephalopathy lesions in rats [9]. A 2013 review by Sikiric et al. consolidated rodent evidence that BPC-157 mitigates NSAID-induced organ toxicity across multiple organ systems [10]. First-in-human IV pilot (Lee and Burgess, 2025): intravenous BPC-157 at 10 mg on day 1 and 20 mg on day 2 (in 250 cc saline, 1-hour infusion) in two healthy adults (a 58-year-old male and a 68-year-old female) was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [5]. Tiny n (n=2); not an efficacy trial; published as a safety pilot only. A 2025 review by Sikiric et al. summarized BPC-157's safety framing and counter-intoxication effects [13]. Regulatory note: the FDA placed BPC-157 in category 2 of the 503A bulk-substances review, which restricts its use in compounded preparations. ## TB-500 — the cytoskeletal and wound-closure arm TB-500 (Ac-LKKTETQ, 889.02 Da) is a synthetic N-acetylated heptapeptide marketed as the actin-binding region of thymosin beta-4 (Tbeta4). The critical distinction: most foundational efficacy data are for the full-length native Tbeta4 (43 amino acids), not the short TB-500 fragment. The two are not equivalent. Wound healing (Malinda et al., 1999): In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction (≥11% by day 7), and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte migration 2-3-fold [6]. These results are for full-length native Tbeta4, not for the TB-500 fragment specifically. Dry-eye RCT (Sosne et al., 2015): in a randomized, placebo-controlled Phase II trial, thymosin beta-4 ophthalmic solution (RGN-259) improved signs and symptoms of dry eye [11]. The ARISE-3 trial (NCT03937882, completed 2020) further assessed safety and efficacy of RGN-259 for dry eye disease [12]. Pro-resolving pathways (Sosne et al., 2024): thymosin beta-4 effects are mediated in part via specialized pro-resolving lipid mediators — a mechanism that may contribute to its anti-inflammatory and repair-promoting profile [14]. Doping detection (Cooper et al., 2012): TB-500 is defined as the synthetic version of LKKTETQ — the actin-binding active site of thymosin beta-4 — with an artificially acetylated N-terminus. An LC-MS method detected the parent peptide and metabolites in equine plasma and urine (LOD 0.02 ng/mL plasma, 0.01 ng/mL urine), establishing the first detection method for anti-doping control of TB-500 in equine sport [8]. WADA status: thymosin beta-4 / TB-500 is on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition. ## KLOW KLOW as a combined formulation has no controlled-trial evidence. The combination rationale — that KPV's anti-inflammatory arm, GHK-Cu's matrix arm, BPC-157's angiogenic arm, and TB-500's cytoskeletal arm could work together as a tissue-repair cascade — is mechanistically plausible but untested. A 2026 Sports Medicine review covering TB-500 and BPC-157 among unapproved peptide therapies noted favorable tissue-repair outcomes in animal models but scarce human safety data with potential for serious harm [7]. The pharmacokinetic mismatch within the blend is a practical constraint: BPC-157 clears in under approximately 30 minutes, the tripeptides KPV and GHK-Cu clear faster still, and the TB-500 fragment behaves differently from full-length thymosin beta-4 [7]. One co-dissolved vial dose cannot deliver all four components to target tissues at matched exposures. ## KLOW blend The KLOW blend is distinct from other multi-peptide formulations in this research space. GLOW is a related blend that lacks the KPV arm (KPV is the 'K' that distinguishes KLOW from GLOW). WOLVERINE is a different peptide set entirely. For the klow results in the literature and how the individual component findings compare across outcome categories, see the dedicated [klow results](/results) page. ## KLOW stack Some research-use communities discuss KLOW in the context of a broader peptide stack. Our research corpus for this domain does not contain documented combination-stack research — and no such data exists in the peer-reviewed literature. Any 'KLOW stack' discussion is community-derived and anecdotal. The pharmacokinetic mismatch within KLOW itself (four components clearing at very different rates in one vial) is already a confound; adding external compounds multiplies the unknowns. ## KLOW peptide blend The KLOW peptide blend is supplied as a lyophilized co-formulation for research handling, typically reconstituted with bacteriostatic water. The peptides remain separate molecules in solution — they do not form a single chemical entity or complex. Copper(II) in GHK-Cu can participate in redox chemistry; co-dissolving it with three other peptides raises a theoretical compatibility consideration that has not been formally characterized for this specific mixture. --- An independent evidence appraisal of four separate research peptide literatures — each finding kept to its own component, the blend's trial column left as the honest blank it is.